Nagpur: Pediatric Trial Phase III Covaxin at the Meditrina Nagpur Meditrina Institute was completed on Saturday.
As many as 20 children in the age group 2-6 were selected for vaccination, but only 14 could be inoculated because three of them had fever and the other three had developed antibodies for Covid-19.
“3 which has antibodies worthy of further learning.
In addition, almost 18% of our total volunteers in the age group 2-18 also have antibodies.
This means, children have recovered without any symptoms,” said the principal’s main principle investigator said Vasant Khalatkar.
The two-year-old children who have antibodies developed without symptoms show that many children in Nagpur have contracted Covid and recovered too.
This important data reduces the threat of infection in children in the third wave projected.
The pediatric population has been divided into three age groups.
Previously, 10 of 50 children in the age group 12 to 18 have been tested positively in an antibody test.
In the younger age group (6-12), five of the 30 children had antibodies while in the youngest age group of 2-6 years, 3 of the 20 chosen children had antibodies.
According to Dr.
Khalatkar, 14 children were given Jab and who completed the target for the Nagpur experimental site.
“Now, these children will be observed for the next 208 days.
Their second jab is after 28 days,” he said.
Experimental coordinator Dr.
Ashish Tajne said even though the trial period was 208 days, the authorization of emergency use could come early.
“The Data and Safety Monitoring Board will meet on the 56th day and see the initial results of the trial.
This is a phase II and III trial, which means authorization of emergency use can be given in between,” he said, adding that Covaxin for adults was given authorization in the same way.
The next two months are important and positive initial results can bring vaccines for children in October-November this year.